Showing 2761-2770 of 10226 results for "".
Effector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urDermwire TV: Topical Caffeine for Hair Growth, Tapinarof for Pediatric AD
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-topical-caffeine-for-hair-growth-tapinarof-for-pediatric-ad/48734/This episode highlights studies showing potential for topical caffeine in hair growth in patients with alopecia areata, as well as recent positive results for tapinarof cream 1% for children with AD. Also, Cutera CEO Taylor Harris talks with Practical Dermatology about the evolving needs of today’sNew Devices and Adaptogens
https://practicaldermatology.com/conferences/science-of-skin-summit-2025/tbd/39741/Jacqueline Watchmaker, MD, explores the intersection of medical devices and adaptogenic therapies in skincare. This video was recorded at the Science of Skin Summit in Austin, TX.DermwireTV: FDA Clears Roflumilast, Guselkumab for Pediatric Populations, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-clears-roflumilast-guselkumab-for-pediatric-populations-plus-more/39732/This episode highlights two new important pediatric approvals for treatments in both atopic dermatitis and psoriatic disease, also features a clip from a recent YoungMD Connect (YMDC) mentorship session with Dr. Tina Bhutani covering both career paths in both academia and industry.The Battle of Biostimulators: PLLA vs Hyperdilute CaHA
https://practicaldermatology.com/youngmd-connect/on-demand-virtual-sessions/the-battle-of-biostimulators-plla-vs-hyperdilute-caha/39250/Modern Aesthetics executive editor Kay Durairaj, MD, FACS, hosts a workshop describing the differences between two dermal filler options, and how she utilizes both in her practice. YoungMD Connect is an editorially independent platform made possible by industry sponsorships. We would like to thank oPressing Unmet Needs in Atopic Dermatitis Management
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37177/Justin Marson, MD, Chief Resident 2024-25 in the Department of Dermatology at SUNY Downstate Health Science University, discusses some of the most important needs in atopic dermatitis diagnostics and treatment.Increased APS Risk for Psoriasis Patients, Plus More
https://practicaldermatology.com/series/dermwire-tv/increased-aps-risk-for-psoriasis-patients-plus-more/39299/This episode highlights research showing increased risk for anti-phospholipid syndrome (APS) in patients with psoriatic disease, as well as research showing increased risks for tuberculosis in patients treated with immunosuppressants. The episode also features a clip from an in-depth discussion arouDWTV Extra: Rocatinlimab Trials
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-rocatinlimab-trials/39044/Clinical investigator Emma Guttman-Yassky, MD, PhD, discusses two sets of data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. The phase 3 ROCKET-Ignite Trial evaluated the efficacy and safety of OX40-receptor targeting with rocatinlimab in moderate-to-severe aDWTV Extra: Vitiligo Ingenuity Award
https://practicaldermatology.com/programs/practical-dermatology/dwtv-extra-vitiligo-ingenuity-award/37869/Hannah Metheny, a student at the University of Miami Miller School of Medicine, discusses winning an Incyte Ingenuity Award in Vitiligo for the "Barriers and Facilitators to Psychosocial Support as an Integral Aspect of Vitiligo Patient Comprehensive Care" project.Biologics Preferred after MACE in PsO, Plus More
https://practicaldermatology.com/series/dermwire-tv/biologics-preferred-after-mace-in-pso-plus-more/37882/In this edition of DermwireTV, new research shows biologic use use after MACE is persistent, signaling strong patient preference; a new study shows that early stress may raise lifelong psoriasis risk; and a new C-Suite Chat highlights a new antibody showing promise in treating atopic dermatitis